Efficacy and safety of saxagliptin monotherapy or added to metformin in Chinese patients with type 2 diabetes mellitus: results from the 24-week, post-marketing SUNSHINE study

Journal of Diabetes

Volumn 8, Issue 6, 2016, Pages 809-815

  Gu, Weiqiong ^a   Liang, Li ^b   Wang, Shengxiang ^e   Wang, Yunzhi ^f   Wu, Yanxiang ^c   Tian, Jian ^d   Yang, Gangyi ^g   Piao, Chunli ⁱ   Li, Yuzhong ^j   Yin, Jianmei ^k   Xin, Xiaoping ^l   Tan, Xingrong ^h   Ning, Guang ^a   Wang, Weiqing ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b People's Hospital of Liaoning Province   (China)

^c Department of Orthopedics 463 Hospital of PLA   (China)

^d SHENYANG MEDICAL COLLEGE   (China)

^e LINYI PEOPLE'S HOSPITAL   (China)

^f BAOTOU MEDICAL COLLEGE   (China)

^g THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^h Chongqing Ninth People's Hospital   (China)

ⁱ CHANGCHUN UNIVERSITY OF CHINESE MEDICINE   (China)

^j Dongguan Guanghua Hospital   (China)

^k TIANJIN THIRD CENTRAL HOSPITAL   (China)

^l PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

more..

Author keywords

efficacy; safety; saxagliptin; type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN; SAXAGLIPTIN;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; BODY MASS; CHINESE; COHORT ANALYSIS; CREATININE CLEARANCE; DIETARY INTAKE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION;

EID: 84990966330     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12360     Document Type: Article

References (25)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med. 1993; 329: 977–86.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837–53.
3. Knowler WC, Fowler SE, Hamman RF et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009; 374: 1677–86.
4. Philippe J, Raccah D. Treating type 2 diabetes: How safe are current therapeutic agents? Int J Clin Pract. 2009; 63: 321–32.
5. DeFronzo RA, Hissa MN, Garber AJ et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009; 32: 1649–55.
6. Goke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract. 2010; 64: 1619–31.
7. Pfutzner A, Paz-Pacheco E, Allen E et al. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab. 2011; 13: 567–76.
8. Rosenstock J, Aguilar-Salinas C, Klein E et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009; 25: 2401–11.
9. Chacra AR, Tan GH, Apanovitch A et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: A randomised controlled trial. Int J Clin Pract. 2009; 63: 1395–406.
10. Hollander P, Li J, Allen E et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009; 94: 4810–9.
11. Jadzinsky M, Pfutzner A, Paz-Pacheco E et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial. Diabetes Obes Metab. 2009; 11: 611–22.
12. Nowicki M, Rychlik I, Haller H et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: A randomised controlled 52-week efficacy and safety study. Int J Clin Pract. 2011; 65: 1230–9.
13. Udell JA, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: Observations from the SAVOR-TIMI 53 Trial. Diabetes Care. 2015; 38: 696–705.
14. Iqbal N, Allen E, Ohman P. Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥65 years) with type 2 diabetes. Clin Interv Aging. 2014; 9: 1479–87.
15. Leiter LA, Teoh H, Braunwald E et al. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 Trial. Diabetes Care. 2015; 38: 1145–53.
16. Pan CY, Yang W, Tou C, Gause-Nilsson I, Zhao J. Efficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: A randomized controlled trial. Diabetes Metab Res Rev. 2012; 28: 268–25.
17. Yang W, Pan CY, Tou C, Zhao J, Gause-Nilsson I. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: A randomized controlled trial. Diabetes Res Clin Pract. 2011; 94: 217–24.
18. Li CJ, Yu Q, Yu P et al. Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes. Exp Clin Endocrinol Diabetes. 2014; 122: 469–76.
19. Cohen ND, Audehm R, Pretorius E, Kaye J, Chapman LH, Colagiuri S. The rationale for combining GLP-1 receptor agonists with basal insulin. Med J Aust. 2013; 199: 246–9.
20. Goke B, Gallwitz B, Eriksson JG, Hellqvist A, Gause-Nilsson I. Saxagliptin vs glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: Long-term (52-week) extension of a 52-week randomised controlled trial. Int J Clin Pract. 2013; 67: 307–16.
21. Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: Systematic review and meta-analysis. Adv Ther. 2012; 29: 14–25.
22. Meigs JB. Epidemiology of cardiovascular complications in type 2 diabetes mellitus. Acta Diabetol. 2003; 40(Suppl. 2): S358–61.
23. National Diabetes Fact Sheet. General Information and National Estimates on Diabetes in the United States, 2011. Atlanta: Centers for Disease Control and Prevention; 2008. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf, accessed 21 Dec, 2015.
24. Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics – 2013 update: A report from the American Heart Association. Circulation. 2013; 127: e6–245.
25. Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369: 1317–26.